charged multivesicular body protein 2AGenealiases: BC-2 · BC2 · CHMP2 · VPS2 · VPS2A
Q-omics provides the consensus-scored CHMP2A profile across patient tissues and cancer cell-line models. CHMP2A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CHMP2A is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, CHMP2A RNA expression shows 18,234 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRC, and THYM as cancer lineages where CHMP2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHMP2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHMP2A survival associations across molecular data types. CHMP2A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHMP2A RNA expression–survival associations across cancer types. High CHMP2A expression shows unfavorable associations in UVM, LGG, UCS, LAML and READ, but favorable associations in UCEC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CHMP2A RNA expression.
This table summarizes CHMP2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CHMP2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHMP2A shows lower tumor expression in KICH and higher tumor expression in KIRC, LIHC, BRCA, CHOL and PAAD. The KIRC box plot shows higher CHMP2A RNA expression in tumor versus normal tissue (log2 FC = +0.744, t-test p < 0.001).
This table shows molecular features associated with CHMP2A in patient tissues and cancer cell lines. In patient samples, CHMP2A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CHMP2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
